This problem is illustrated by the attempts to validate ERCC1 as a predictive biomarker for chemotherapy for non-small cell lung cancer, which failed because the commercial antibody used for ERCC1 did not perform as expected [2,3]. This evidence concerns the gene ERCC1 and non-small cell lung carcinoma.